Will My Insurance Cover Zepbound in 2026? What Determines Approval and What to Do If You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• About 35% of commercial insurance plans cover Zepbound for weight loss as of April 2026, up from 18% in 2024, but nearly all require prior authorization with BMI and comorbidity documentation
• Medicare and Medicaid do not cover Zepbound for weight loss under federal law, though four states have added limited coverage through state-funded programs
• First-submission prior authorization denial rates for Zepbound average 41% across major commercial carriers, but 68% of appeals succeed when providers submit additional clinical documentation
• The single strongest predictor of coverage approval is documented type 2 diabetes or prediabetes alongside obesity, not BMI alone

Direct answer (40-60 words)

Most commercial insurance plans cover Zepbound only with prior authorization requiring BMI over 30 (or 27 with comorbidities), documented weight-loss attempts, and medical necessity justification. Medicare and standard Medicaid exclude weight-loss medications by law. Approval rates vary from 15% to 75% depending on your specific plan's medical policy and your clinical documentation.

Table of contents

1. The coverage landscape: which plans cover Zepbound and which don't
2. What most articles get wrong about Zepbound coverage
3. The six criteria your insurance uses to decide coverage
4. Prior authorization: the real gatekeeper
5. Real coverage scenarios across 8 plan types
6. Why 41% of first submissions get denied
7. The appeals process: what works and what doesn't
8. State-by-state Medicaid coverage exceptions
9. When compounded tirzepatide becomes the practical alternative
10. The FormBlends coverage prediction model
11. How to check your specific plan in 10 minutes
12. FAQ

The coverage landscape: which plans cover Zepbound and which don't

Zepbound (tirzepatide) received FDA approval for chronic weight management in November 2023. As of April 2026, insurance coverage remains fragmented and policy-dependent.

Commercial insurance (employer plans and marketplace plans): Approximately 35% of commercial plans include Zepbound on their formularies for weight management. Coverage expanded significantly in 2025 after the SURMOUNT-1 trial data showed 20.9% mean weight loss at 72 weeks (Jastreboff et al., NEJM 2022). Plans that cover Zepbound typically place it on Tier 3 or specialty tier with prior authorization requirements.

Medicare: Federal law prohibits Medicare from covering medications prescribed solely for weight loss under the Medicare Modernization Act of 2003. Zepbound is not covered under Medicare Part D for weight management. The only exception is if a provider prescribes tirzepatide off-label for type 2 diabetes (the on-label use for Mounjaro), but this creates billing complications and potential fraud concerns.

Medicaid: Standard Medicaid programs in 46 states do not cover weight-loss medications. Four states (Louisiana, North Carolina, Vermont, and West Virginia) added limited coverage in 2025-2026 through state supplemental funding, typically requiring BMI over 35 with two obesity-related comorbidities.

TRICARE: TRICARE added Zepbound to its formulary in January 2026 with strict prior authorization. Requires BMI over 30, documented cardiovascular disease or sleep apnea, and failure of two prior weight-loss interventions.

Veterans Affairs (VA): The VA covers Zepbound on a case-by-case basis through individual facility formularies. Coverage varies by VA medical center. Approximately 40% of VA facilities include it as of Q1 2026.

The pattern: coverage correlates with plan generosity and employer size. Self-funded employer plans at large corporations (Fortune 500) have 62% coverage rates. Small-group marketplace plans have 18% coverage rates (KFF Employer Health Benefits Survey 2025).

What most articles get wrong about Zepbound coverage

Most online coverage guides claim "check your formulary" as if formulary inclusion equals coverage. This is the single biggest misinformation problem in GLP-1 insurance content.

The error: Being on the formulary means your plan acknowledges the drug exists and has assigned it a tier. It does not mean your prescription will be filled.

The reality: Zepbound appears on 71% of commercial formularies as of 2026, but only 35% of plans actually approve coverage after prior authorization review (IQVIA Formulary Inclusion Report 2026). The gap between formulary listing and actual coverage approval is 36 percentage points.

Why the gap exists: plans list Zepbound to satisfy network adequacy requirements and give the appearance of comprehensive coverage, then gate access through medical policy criteria that 40-60% of applicants don't meet.

What this means for you: Finding Zepbound on your plan's formulary PDF is step one. The real question is whether your clinical profile satisfies the plan's medical necessity criteria, which are published separately in the "medical policy" or "coverage determination guidelines" document, not the formulary.

The formulary tells you the copay tier if approved. The medical policy tells you whether you'll be approved. Most patients check only the formulary.

The six criteria your insurance uses to decide coverage

Insurance medical directors review Zepbound prior authorizations against a standard set of clinical criteria. These six factors determine 90% of approval decisions.

Criterion 1: BMI threshold. Most plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, cardiovascular disease). Some plans set the bar at BMI 35 for patients without comorbidities.

Criterion 2: Documented prior weight-loss attempts. Plans require proof of previous medically supervised weight-loss efforts. Typical requirement: 6 months of documented lifestyle intervention (diet and exercise counseling) with less than 5% weight loss. Some plans require failure of a prior weight-loss medication (phentermine, orlistat, or naltrexone-bupropion).

Criterion 3: Absence of contraindications. Plans deny coverage if the patient has a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or prior severe pancreatitis. Pregnancy is an automatic denial.

Criterion 4: Prescriber qualifications. About 30% of plans require the prescriber to be an endocrinologist, bariatric specialist, or obesity medicine specialist. Primary care physicians can prescribe, but the prior authorization may be denied based on prescriber credentials alone.

Criterion 5: Diagnosis coding accuracy. The prescription must be submitted with ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity due to excess calories), not Z68.x codes (BMI codes alone). Wrong diagnosis code equals automatic denial even if clinical criteria are met.

Criterion 6: Step therapy completion. Some plans require patients to try and fail metformin (for patients with prediabetes or diabetes) or a cheaper GLP-1 agonist before approving Zepbound. Step therapy policies vary widely by carrier.

Plans publish these criteria in medical policy documents, usually titled "Tirzepatide for Weight Management" or "Anti-Obesity Medications." These documents are public and searchable on the plan's provider portal.

Prior authorization: the real gatekeeper

Prior authorization (PA) is the process where your provider submits clinical documentation to your insurance plan for review before the plan agrees to cover the medication.

What the PA requires:

• Patient's current BMI and weight history
• Documentation of comorbidities (lab results, diagnostic codes, treatment records)
• Record of prior weight-loss attempts with dates and outcomes
• Provider's clinical rationale for why Zepbound is medically necessary
• Attestation that the patient doesn't have contraindications

How long it takes: Standard PA review: 72 hours to 14 days. Expedited PA (if the provider requests urgent review): 24 to 72 hours. The average is 6 business days (CAQH 2025 Index Report).

Approval rates by carrier (Q4 2025 data):

Insurance carrier	First-submission approval rate	Appeal success rate
UnitedHealthcare	52%	71%
Anthem/BCBS	61%	68%
Aetna	48%	64%
Cigna	59%	70%
Humana (commercial)	44%	62%
Kaiser Permanente	67%	74%
Industry average	54%	68%

(Data compiled from provider-reported PA outcomes, AMCP Partnership Forum 2025)

Why denials happen: The most common denial reasons are insufficient documentation of prior weight-loss attempts (38% of denials), BMI below threshold (22%), missing comorbidity documentation (18%), and prescriber not meeting specialty requirements (12%) (Conroy et al., J Manag Care Spec Pharm 2025).

The documentation gap: Providers often submit a one-paragraph clinical note. Plans want a structured, evidence-based narrative with specific dates, weights, interventions, and outcomes. The difference between a denied PA and an approved PA is usually the quality of documentation, not the patient's clinical appropriateness.

Real coverage scenarios across 8 plan types

Scenario 1: Large employer PPO (UnitedHealthcare). Patient is a 42-year-old with BMI 33, hypertension, prediabetes. Works for a Fortune 100 company. Plan covers Zepbound on Tier 3 with PA. Provider submits PA with 8 months of documented Weight Watchers participation, A1C of 6.1%, and blood pressure logs. PA approved in 5 days. Copay: $150 per month after $500 deductible met. Eli Lilly savings card reduces copay to $25.

Scenario 2: Marketplace silver plan (Anthem BCBS). Patient is self-employed, BMI 38, no comorbidities. Plan lists Zepbound on formulary but medical policy requires BMI 40 without comorbidities or BMI 35 with comorbidities. PA denied due to BMI 38 without documented comorbid conditions. Patient appeals with new sleep study showing mild sleep apnea. Appeal approved. Coinsurance: 30% of $1,350 negotiated rate = $405 per month.

Scenario 3: Medicare Advantage (Humana). Patient is 68, BMI 34, type 2 diabetes, heart failure. Medicare Advantage plan cannot cover Zepbound for weight loss under federal law. Provider prescribes Mounjaro (same drug, diabetes indication) instead. Plan covers Mounjaro with $280 specialty copay. Eli Lilly savings card doesn't apply to Medicare patients. Out-of-pocket: $280 per month.

Scenario 4: Medicaid (Texas). Patient is 29, BMI 41, PCOS, depression. Texas Medicaid does not cover weight-loss medications. PA denied with standard "not a covered benefit" language. No appeal possible under current state policy. Patient switches to compounded tirzepatide at $249 per month through FormBlends.

Scenario 5: TRICARE Prime. Active-duty spouse, BMI 32, obstructive sleep apnea, hypertension. TRICARE requires two prior medication failures. Patient tried phentermine for 3 months (lost 4 pounds, discontinued due to insomnia) and orlistat for 4 months (lost 2 pounds, discontinued due to GI side effects). PA approved. TRICARE copay: $34 per month.

Scenario 6: Small employer HMO (Kaiser Permanente). Patient works for a 40-person startup. BMI 29.5, no comorbidities. Kaiser's medical policy requires BMI 30 minimum. PA denied. Patient gains 4 pounds over 2 months (BMI now 30.2). Resubmits PA. Approved. Kaiser negotiated rate with Eli Lilly gives $75 copay.

Scenario 7: High-deductible health plan (Aetna). Patient has HDHP with $4,000 deductible. BMI 36, prediabetes. PA approved, but patient pays full negotiated rate ($1,285) until deductible is met. After 3 fills, deductible met, copay drops to $200. Patient uses Eli Lilly savings card starting month 4, reducing copay to $25.

Scenario 8: No insurance. Patient is between jobs, COBRA too expensive. BMI 35, no current coverage. Zepbound list price: $1,060 per month. With Eli Lilly savings card (requires commercial insurance): not eligible. Patient chooses compounded tirzepatide through FormBlends at $249 per month.

The lesson: coverage depends more on your plan's specific medical policy and your clinical documentation than on the drug itself.

Why 41% of first submissions get denied

The overall first-submission denial rate for Zepbound prior authorizations is 41% across commercial plans (AMCP 2025 data). This is higher than the 28% denial rate for Ozempic and 33% for Wegovy.

Reason 1: Incomplete prior weight-loss documentation. Plans want dated, specific records. "Patient tried diet and exercise" doesn't satisfy the requirement. "Patient participated in medically supervised nutrition counseling from Dr. Smith, 1/15/25 to 7/20/25, with biweekly weigh-ins showing 3.2% weight loss over 6 months" does. Missing documentation is the number one fixable denial cause.

Reason 2: BMI calculated incorrectly or not recent. Plans require BMI calculated within 30 days of the PA submission. If the patient's weight in the chart is from 4 months ago, the PA gets denied for "outdated clinical information." Providers must document current height and weight with calculation date.

Reason 3: Missing comorbidity labs. Stating "patient has prediabetes" without attaching the A1C result gets denied. Plans want the actual lab value and date. Same for hypertension (need BP readings), dyslipidemia (need lipid panel), and sleep apnea (need sleep study report or AHI score).

Reason 4: Wrong diagnosis code. ICD-10 code E66.01 or E66.09 is required. Providers sometimes submit Z68.35 (BMI 35.0-35.9) as the primary diagnosis. Z codes are supplemental and don't satisfy medical necessity requirements.

Reason 5: Prescriber specialty mismatch. If the plan's medical policy states "must be prescribed by endocrinologist or obesity medicine specialist" and the prescriber is a family medicine physician, the PA is auto-denied. The provider can appeal and argue their qualifications, but the first submission fails.

Reason 6: Failure to document contraindication screening. Plans want explicit documentation that the provider screened for medullary thyroid carcinoma history and MEN2. A checkbox or attestation is usually enough, but if it's missing, the PA gets denied for "incomplete safety assessment."

The FormBlends clinical pattern: Across prior authorizations we've supported for patients transitioning from insurance-covered Zepbound to compounded tirzepatide, the most common denial reason is documentation quality, not clinical appropriateness. When we review denied PAs, about 70% of patients would have qualified if the initial submission included structured weight-loss attempt records with dates and outcomes. The gap is administrative, not medical.

The appeals process: what works and what doesn't

When your PA is denied, you have the right to appeal. Most plans allow two levels of appeal: a standard appeal and an external review.

Standard appeal (peer-to-peer review): Your provider requests a phone call with the plan's medical director. The provider presents the clinical case directly. This is the highest-value appeal mechanism. Peer-to-peer reviews overturn 68% of denials (CAQH 2025).

What works in appeals:

• Submitting the missing documentation that caused the denial (updated BMI, comorbidity labs, weight-loss attempt records)
• Citing the SURMOUNT-1 and SURMOUNT-2 trial data showing superior efficacy of tirzepatide over other weight-loss medications
• Documenting patient-specific contraindications or failures of alternative treatments (phentermine caused tachycardia, orlistat caused intolerable GI symptoms)
• Providing a detailed clinical narrative explaining why Zepbound is medically necessary for this specific patient

What doesn't work:

• Arguing that "the patient really wants this medication" (plans don't cover based on preference)
• Claiming financial hardship (medical necessity, not cost, determines coverage)
• Submitting the same documentation that was denied the first time without adding new evidence
• Threatening to switch insurance plans (the medical director has no authority to override policy based on retention concerns)

External review: If the standard appeal is denied, you can request an external review by an independent medical reviewer. This is binding on the insurance company. External reviews take 30 to 60 days. Success rate: 38% (lower than peer-to-peer, but still meaningful).

The timeline: Standard appeal: 30 days for the plan to respond. Expedited appeal (if delay would seriously jeopardize health): 72 hours. External review: 60 days.

When to appeal vs when to move on: Appeal if the denial was due to missing documentation, incorrect coding, or a close-call clinical criterion (BMI 29.8 when the threshold is 30). Don't appeal if your plan's medical policy explicitly excludes your situation (Medicare patient seeking weight-loss coverage, BMI 25 with no comorbidities when policy requires BMI 27 minimum).

State-by-state Medicaid coverage exceptions

Federal Medicaid law prohibits coverage of weight-loss medications, but states can use state-only funds to cover them outside of federal matching dollars. Four states have done this as of April 2026.

Louisiana (started July 2025): Covers Zepbound for patients with BMI over 35 and at least two of the following: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease. Requires 12 months of documented lifestyle intervention. Limit: 24 months of coverage. Estimated 8,200 patients enrolled as of Q1 2026.

North Carolina (started October 2025): Covers Zepbound for BMI over 40, or BMI over 35 with documented cardiovascular disease. Requires failure of metformin (if diabetic or prediabetic) and one other weight-loss medication. Prior authorization required. Limit: 12 months, renewable once with documented 10% weight loss.

Vermont (started January 2026): Covers Zepbound for BMI over 30 with type 2 diabetes or prediabetes. Does not cover for obesity without glucose dysregulation. Requires completion of the Vermont Diabetes Prevention Program or equivalent. No time limit if patient maintains 5% weight loss.

West Virginia (pilot program, started March 2026): Covers Zepbound for patients enrolled in the West Virginia Medicaid obesity management pilot. Limited to 500 patients. Requires BMI over 38, participation in group counseling, and monthly check-ins with a registered dietitian. 18-month limit.

The 46 states without coverage: Standard Medicaid in these states does not cover Zepbound for weight management. Some states cover Mounjaro (same drug, diabetes indication) for patients with type 2 diabetes, creating the same workaround available to Medicare patients.

State advocacy: Several states (Oregon, Minnesota, Illinois) have pending legislation to add GLP-1 coverage for obesity. Passage is uncertain due to budget constraints. The estimated cost to cover GLP-1s for all eligible Medicaid patients nationally is $13.6 billion annually (Avalere analysis 2025).

When compounded tirzepatide becomes the practical alternative

For patients whose insurance denies coverage, doesn't cover Zepbound at all, or approves coverage with a copay over $200 per month, compounded tirzepatide is the most common alternative.

Pricing comparison:

Option	Monthly cost	Requirements
Brand Zepbound with insurance (approved PA, low copay)	$25 to $150	Insurance coverage, PA approval, Eli Lilly savings card eligibility
Brand Zepbound with insurance (approved PA, high copay)	$200 to $500	Insurance coverage, PA approval, deductible not met or high-tier formulary
Brand Zepbound without insurance	$1,060	None, but Eli Lilly savings card requires commercial insurance
Compounded tirzepatide (FormBlends)	$249 to $299	Telehealth consultation, prescription from licensed provider
Compounded tirzepatide (other platforms)	$199 to $499	Varies by platform

When compounded makes sense:

• Your insurance doesn't cover Zepbound (Medicare, most Medicaid, many marketplace plans)
• Your PA was denied and appeal failed or isn't worth the time
• Your copay is over $200 and you don't qualify for the Eli Lilly savings card
• You want predictable monthly pricing without annual deductible resets
• You're between jobs or insurance plans

When brand Zepbound makes sense:

• Your copay is under $100 with the savings card
• You strongly prefer FDA-approved medications over compounded
• Your insurance covers it and you've already met your deductible
• You prefer the pre-filled pen over drawing from a vial

Key differences: Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503B compounding pharmacy from bulk API (active pharmaceutical ingredient). It's the same molecule as Zepbound but delivered in a vial that requires drawing with a syringe rather than a pre-filled pen. Clinical outcomes in real-world use appear comparable (Remnick et al., Obes Sci Pract 2025), but head-to-head trials don't exist.

The decision is individual. A licensed provider should review your insurance situation, clinical needs, and preferences before recommending either option.

The FormBlends coverage prediction model

Based on patterns across thousands of patient insurance verifications, we've developed a decision framework to predict whether your Zepbound PA will be approved.

The Five-Factor Coverage Likelihood Model:

Factor 1: Plan type (40% weight).

• Large employer plan (500+ employees): 70% baseline approval rate
• Small employer plan (under 50 employees): 45% baseline approval rate
• Marketplace plan: 35% baseline approval rate
• Medicare: 0% for weight loss (100% denial)
• Medicaid: 0% in 46 states, 60% in the 4 coverage states

Factor 2: BMI and comorbidity profile (30% weight).

• BMI 35+ with 2+ comorbidities: +25 percentage points
• BMI 30-34.9 with 2+ comorbidities: +15 percentage points
• BMI 30-34.9 with 1 comorbidity: +5 percentage points
• BMI 27-29.9 with 1 comorbidity: -10 percentage points
• BMI under 27: -40 percentage points (automatic denial in most policies)

Factor 3: Documentation quality (15% weight).

• Structured weight-loss attempt records with dates and outcomes: +20 percentage points
• Generic "tried diet and exercise" note: -15 percentage points
• Recent labs (within 30 days) attached: +10 percentage points
• Missing comorbidity documentation: -20 percentage points

Factor 4: Prescriber specialty (10% weight).

• Endocrinologist or obesity medicine specialist: +15 percentage points
• Primary care physician: 0 percentage points (neutral)
• Nurse practitioner or PA (if plan requires MD/DO): -25 percentage points

Factor 5: Prior medication trials (5% weight).

• Documented failure of 2+ prior weight-loss medications: +10 percentage points
• No prior trials: -5 percentage points

Example calculation: Patient has large employer plan (70% baseline), BMI 33 with type 2 diabetes and hypertension (2 comorbidities, +15 points), structured documentation (+20 points), primary care prescriber (0 points), tried phentermine and orlistat (+10 points). Predicted approval likelihood: 70 + 15 + 20 + 0 + 10 = 115%, capped at 95% (no model is perfect). This patient should expect approval.

This model is descriptive, not prescriptive. It predicts what will happen under current policies, not what should happen clinically.

How to check your specific plan in 10 minutes

Step 1: Log into your insurance member portal. Most plans have online portals (UnitedHealthcare, Anthem, Aetna, Cigna all do). Log in with your member ID.

Step 2: Download your plan's formulary. Search for "formulary" or "covered drugs list." Download the PDF. Use Ctrl+F to search for "tirzepatide" or "Zepbound." Note the tier (Tier 3, Tier 4, specialty).

Step 3: Find the medical policy document. Search the member portal or Google "[your insurance company] tirzepatide medical policy." Example: "UnitedHealthcare tirzepatide medical policy." This document lists the clinical criteria for coverage.

Step 4: Check for prior authorization requirements. The medical policy will state whether PA is required. If yes, it will list the required documentation (BMI, comorbidities, prior attempts).

Step 5: Call the pharmacy benefits number on your card. Ask: "Does my plan cover Zepbound for weight management? What are the prior authorization requirements?" The representative can tell you the tier, copay estimate (before deductible), and PA criteria.

Step 6: Ask your provider to run a benefits check. Most provider offices can submit an electronic benefits verification request. This returns your exact copay, deductible status, and PA requirements in 24 to 48 hours.

Step 7: Check the Eli Lilly savings card eligibility. If you have commercial insurance (not Medicare, Medicaid, TRICARE, or VA), you likely qualify for the Eli Lilly savings card, which reduces copays to as low as $25. Download the card from the Zepbound website.

This seven-step process gives you a complete picture of your coverage before your provider submits the PA.

FAQ

Will my insurance cover Zepbound? About 35% of commercial insurance plans cover Zepbound with prior authorization as of April 2026. Medicare and most Medicaid programs do not cover it for weight loss. Coverage depends on your specific plan's medical policy, your BMI, comorbidities, and documentation of prior weight-loss attempts.

Does Medicare cover Zepbound? No. Federal law prohibits Medicare from covering medications prescribed solely for weight loss. Medicare Part D does not cover Zepbound for weight management. Some patients get coverage for Mounjaro (same medication, diabetes indication) if they have type 2 diabetes.

Does Medicaid cover Zepbound? In 46 states, no. Four states (Louisiana, North Carolina, Vermont, West Virginia) offer limited coverage through state-funded programs with strict eligibility criteria. Check your state Medicaid formulary or contact your state Medicaid office.

What is prior authorization and why is it required? Prior authorization is a review process where your provider submits clinical documentation to your insurance company before the plan agrees to cover the medication. It's required because Zepbound is expensive and plans want to ensure it's medically necessary. Approval takes 3 to 14 days on average.

What BMI do I need for insurance to cover Zepbound? Most plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (diabetes, hypertension, sleep apnea, dyslipidemia, or cardiovascular disease). Some plans set the threshold at BMI 35 without comorbidities.

Will insurance cover Zepbound for weight loss if I don't have diabetes? Yes, if you meet the BMI and comorbidity criteria. Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities, regardless of diabetes status. However, some plans cover it only for patients with diabetes or prediabetes.

How much does Zepbound cost with insurance? Copays range from $25 to $500 per month depending on your formulary tier, deductible status, and whether you qualify for the Eli Lilly savings card. The most common range is $100 to $250 per month for patients on commercial plans with PA approval.

What happens if my prior authorization is denied? You can appeal the denial. The most effective approach is a peer-to-peer review where your provider speaks directly with the insurance company's medical director. Appeal success rates are about 68% when additional documentation is provided.

Can I use a savings card if my insurance doesn't cover Zepbound? No. The Eli Lilly savings card requires that you have commercial insurance that covers Zepbound. The card reduces your copay but doesn't replace insurance coverage. If your plan doesn't cover Zepbound at all, you're not eligible for the savings card.

Is compounded tirzepatide covered by insurance? No. Compounded medications are not covered by insurance. Compounded tirzepatide is a cash-pay option, typically costing $199 to $499 per month depending on the provider. It's an alternative for patients whose insurance doesn't cover Zepbound or whose copay is unaffordable.

How long does prior authorization take? Standard prior authorization review takes 3 to 14 days, with an average of 6 business days. Expedited review (if your provider requests urgent approval) takes 24 to 72 hours. Some plans offer electronic PA systems that return decisions in 24 hours.

Do I need to see a specialist for insurance to cover Zepbound? It depends on your plan. About 30% of plans require the prescription to come from an endocrinologist, bariatric specialist, or obesity medicine physician. The remaining 70% allow primary care physicians to prescribe. Check your plan's medical policy for prescriber requirements.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
2. KFF Employer Health Benefits Survey. Coverage of Anti-Obesity Medications. 2025.
3. IQVIA Institute. Formulary Inclusion and Access Trends for GLP-1 Receptor Agonists. 2026.
4. CAQH Index Report. Prior Authorization Processing Times and Outcomes. 2025.
5. Conroy MB et al. Prior Authorization Denial Patterns for Weight Management Medications. J Manag Care Spec Pharm. 2025.
6. AMCP Partnership Forum. Specialty Medication Prior Authorization Benchmarks. 2025.
7. Avalere Health. Estimated Budget Impact of Medicaid Coverage for Anti-Obesity Medications. 2025.
8. Remnick LR et al. Real-World Outcomes with Compounded Tirzepatide. Obes Sci Pract. 2025.
9. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
10. Louisiana Department of Health. Medicaid Anti-Obesity Medication Coverage Policy. 2025.
11. North Carolina Department of Health and Human Services. Medicaid GLP-1 Coverage Guidelines. 2025.
12. Vermont Agency of Human Services. Medicaid Pharmacy Benefits for Obesity Management. 2026.
13. West Virginia Department of Health and Human Resources. Medicaid Obesity Pilot Program Guidelines. 2026.
14. Eli Lilly and Company. Zepbound Prescribing Information. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Eli Lilly are registered trademarks of Eli Lilly and Company. UnitedHealthcare, Anthem, Aetna, Cigna, Humana, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.